CellWell record HH-0255
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT)
Bhatt DL, Steg PG, Miller M, et al.
New England Journal of Medicine ยท 2019
In plain language
In statin-treated patients with elevated triglycerides, high-dose EPA (icosapent ethyl) was associated with a lower rate of major cardiovascular events versus placebo.
- Design
- Randomized controlled trial
- Studied in
- Human
Cite this record: https://thecellwell.org/studies/HH-0255
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.